Showing 2051-2060 of 2192 results for "".
- FDA Approves Selumetinib for Children with Neurofibromatosis Type 1https://practicalneurology.com/news/fda-approves-selumetinib-for-children-with-neurofibromatosis-type-1/2469227/The Food and Drug Administration (FDA) approved selumetinib (Koselugo; AstraZeneca, Wilmington, DE) for the treatment of children age 2 years or more who have neurofibromatosis type 1 (NF1). Selumetinib, a kinase inhibitor, is approved for treatment of symptomatic inoperable plexiform neurofibrom
- Long-Term Exposure to Air Pollution and Rate of Cognitive Declinehttps://practicalneurology.com/news/long-term-exposure-to-air-pollution-and-rate-of-cognitive-decline/2469226/In a study published in Neurology researchers found an association of air pollution levels with cognitive impairment and decline in 1 of 2 large groups but not both. Both groups were ethnically and racially diverse and lived in the Northern Manhattan area of New York City. Participant's resid
- Rimegepant, Recently Approved for Acute Migraine Treatment, Now Available to Prescribe Via Telemedicinehttps://practicalneurology.com/news/rimegepant-recently-approved-for-acute-migraine-treatment-now-available-to-prescribe-via-telemedicine/2469221/Rimegepant (Nurtec; Biohaven, New Haven, CT), which was recently approved for acute treatment of migraine, is now available to be prescribed via a telemedicine platform (Cove, New York, NY). This is especially important in this unprecedented time of decreased access to routine health care, d
- FDA Authorizes Prescription Digital Therapeutic for Chronic Insomniahttps://practicalneurology.com/news/fda-authorizes-prescription-digital-therapeutic-for-chronic-insomnia/2469211/The Food and Drug Administration (FDA) has granted authorization for a prescription digital therapeutic (PDT) (Somryst, Pear Therapeutics, Boston, MA) intended for treating individuals age 22 years or more with chronic insomnia. The therapy is a 9-week PDT that can be used on a mo
- FDA Approves Ozanimod for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-ozanimod-for-relapsing-multiple-sclerosis/2469208/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Investigational Nonsteroidal Edaslonexent Treatment for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/investigational-nonsteroidal-edaslonexent-treatment-for-duchenne-muscular-dystrophy/2469205/Treatment of boys with Duchenne Muscular Dystrophy (DMD), age 4 to 7 years and never been exposed to steroids (n=31), led to growth patterns that were similar to children without DMD. Although the boys' growth rates were age normative, weight increase was less than the mean for boys at this a
- Vazegepant Advances to Phase 3 Trials for Acute Migraine Treatmenthttps://practicalneurology.com/news/vazegepant-advances-to-phase-3-trials-for-acute-migraine-treatment/2469198/It has previously been reported that intranasal vazegepant (Biohaven Pharmaceutical, New Haven, CT) 10 mg and 20 mg achieved statistical superiority to placebo on the coprimary regulatory endpoints of pain freedom and freedom from most bothersome symptoms at 2 hours in a phase 2/3 dose-finding tr
- Head Sensors to Measure Frequency and Severity of Head Impact Have High Rate of False Positiveshttps://practicalneurology.com/news/head-sensors-to-measure-frequency-and-severity-of-head-impact-have-high-rate-of-false-positives/2469187/Concussion risk in young athletes has prompted researchers to use a variety of head impact sensors to measure frequency and severity of impacts during sports. A new study from Children's Hospital of Philadelphia (CHOP) shows these head sensors can record a large number of false positive impac
- Daytime Sleepiness in People Over Age 65 May Be at Risk for Medical Conditionshttps://practicalneurology.com/news/daytime-sleepiness-in-people-over-age-65-may-be-at-risk-for-medical-conditions/2469179/According to a preliminary study, people over age 65 who experience daytime sleepiness may be at risk of developing medical conditions such as diabetes, cancer, and high blood pressure. The study involved 10,930 participants and researchers interviewed participants over the phone twice, 3 years a
- FDA Approves Rimegepant for Acute Treatment of Migraine in Adultshttps://practicalneurology.com/news/fda-approves-rimegepant-for-acute-treatment-of-migraine-in-adults/2469170/The Food and Drug Administration (FDA) has approved rimegepant (Nurtec; Biohaven, New Haven, CT) for the acute treatment of migraine in adults. Rimegepant is administered as a fast-acting orally disintegrating table and a single dose of 75 mg provides pain relief within 1 hour. Rimegepant also ha